©Reuters.
STAMFORD, Conn. – Cara Therapeutics, Inc. (NASDAQ: NASDAQ:), a commercial-stage biopharmaceutical company, will call on March 4, 2024 at 4:30 p.m. ET to discuss its fourth quarter. We have scheduled a conference and audio web livecast. and 2023 full-year financial results and company updates.
The company, known for its focus on treating itch, is inviting interested parties to register for a conference call, where they will receive a dial-in number and a unique PIN to access the event. Additionally, the call will be accessible as a live audio webcast and as an archived replay from the Investors section of the company's website.
Cara Therapeutics has made significant contributions to the field of pruritus treatment with its FDA-approved KORSUVA® injection. This is currently the only FDA-approved treatment for moderate to severe pruritus in adults undergoing hemodialysis due to chronic kidney disease. Based on this, the company is also developing an oral formulation of difelikephalin. The formulation is being evaluated through a Phase 2/3 clinical program in patients with paresthesia pain, a condition characterized by chronic itching in the upper back and for which there is no FDA-approved treatment.
Upcoming financial results and company updates are expected to provide clarity on the company's performance and strategic direction, including progress in its product pipeline. As a leader in the field, Cara Therapeutics continues to focus on new treatment paradigms aimed at improving patient outcomes.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
